Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03510104 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic and Safety Study of MRX-2843 in Adults With Relapsed/Refractory Advanced and/or Metastatic Solid Tumors
A Phase 1 study, sponsored by Meryx.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT03510104 is a Phase 1 study that has completed, run by Meryx. The registered enrollment target is 42 participants.
The verdict
NCT03510104, a Phase 1 study, has completed, sponsored by Meryx.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
This first-in-human open-label, dose escalation study is designed to evaluate the safety, tolerability, and PK of MRX-2843 in subjects with relapsed/refractory advanced and/or metastatic solid tumors.
Interventions
- DRUG MRX-2843
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2018-05-22 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03510104
The ClinicalTrials.gov registry entry for NCT03510104 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Meryx, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MRX-2843 is the first listed.
NCT03510104 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03510104 about?
NCT03510104 is a clinical study titled "Pharmacokinetic and Safety Study of MRX-2843 in Adults With Relapsed/Refractory Advanced and/or Metastatic Solid Tumors". This first-in-human open-label, dose escalation study is designed to evaluate the safety, tolerability, and PK of MRX-2843 in subjects with relapsed/refractory advanced and/or metastatic solid tumors.
What is the current status of trial NCT03510104?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2018-05-22. Estimated completion is 2025-12-31.
What interventions are being tested in trial NCT03510104?
The interventions under investigation include: MRX-2843 (DRUG).
Who is sponsoring clinical trial NCT03510104?
This trial is sponsored by Meryx, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.